Lupin licenses bioadhesive delivery technology to Salix
This article was originally published in Scrip
Executive Summary
Lupin has granted Salix Pharmaceuticals exclusive rights in the US to its bioadhesive drug delivery technology for use with Salix's diarrhoea treatment, rifaximin.